drugset / Trial / NCT02981069
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
Phase 4
Completed
90 enrolled
The University of Texas Health Science Center at San Antonio
AstraZeneca · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.
Timeline
- Start
- 2017-12-15
- Primary completion
- 2022-07-14
- Completion
- 2023-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Exenatide | Peptide | 2 mg | Subcutaneous |